OncoMatch/Clinical Trials/NCT06944457
Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor
Is NCT06944457 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MPD-1 for cancer.
Treatment: MPD-1 — A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Required: PTEN loss
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available existing standard therapy
has used all available existing standard therapy but tumor progression is confirmed and further treatment tool is absent, or patient showing resistant or inadequate to standard therapy
Cannot have received: anthracycline
Patients without the history of administration of anthracycline drugs and/or anthracene
Lab requirements
Blood counts
WBC ≥ 3,500/mm3; ANC ≥ 1,500/mm3 (without CSF within 2 weeks prior to C1D1); platelets ≥ 100,000/mm3 (without transfusion within 2 weeks prior to C1D1); hemoglobin ≥ 10 g/dL (without transfusion within 2 weeks prior to C1D1); INR ≤ 1.5x ULN
Kidney function
serum creatinine ≤ 1.5x ULN
Liver function
total bilirubin ≤ 1.5x ULN (Gilbert syndrome exception); AST, ALT ≤ 2.5x ULN (≤ 5x ULN with liver metastasis); albumin ≥ 2.5 g/dL
Cardiac function
LVEF ≥ 50%, no congestive heart failure NYHA class II or higher, no myocarditis, myocardial infarction or unstable angina within 24 weeks before C1D1, no uncontrolled cardiac dysrhythmia, no coronary artery disease
appropriate hematologic, kidney, and liver function confirmed by the following laboratory test... LVEF <50%, congestive heart failure with NYHA class II or higher, history of myocarditis, myocardial infarction or unstable angina within 24 weeks before C1D1, uncontrolled cardiac dysrhythmia by appropriate medication, coronary artery disease, etc.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify